
In this episode of The Issue, Sara Johnson Davis, Senior Director of Government Affairs at Ardelyx and former Vice President, Head of Patient Advocacy & Policy at Fulcrum Therapeutics, joins host Sanjay D’Souza, PhD, to discuss the essential role of patient advocacy in cell and gene therapy. The conversation covers the evolving role of patient advocacy in drug development, from early research and clinical trial design to policy, commercialization, and access. Sara shares lessons from the sickle cell disease community, reflects on the transition of gene editing from experimental science to approved therapy, and explains why trust, infrastructure, and policy are essential to ensuring transformative treatments actually reach patients. Music: ‘Bright New Morning’ by Steven O’Brien – released under CC-BY 4.0. https://www.steven-obrien.net/Show your support for ASGCT!: https://asgct.org/membership/donateSee omnystudio.com/listener for privacy information.
Podzilla Summary coming soon
Sign up to get notified when the full AI-powered summary is ready.
Free forever for up to 3 podcasts. No credit card required.

An Ex Vivo Human Liver Model for Lentiviral Vector Profiling

From Aspiring Astronaut to CAR-T Pioneer: A Journey of Serendipity with Bruce Levine, PhD

Advancements in Pediatric Cancer Therapy with Nirali Shah and Timothy Cripe

Using AI to Drive Innovation in CGT with Le Cong, PhD
Free AI-powered recaps of ASGCT Podcast Network and your other favorite podcasts, delivered to your inbox.
Free forever for up to 3 podcasts. No credit card required.